As the COVID-19 pandemic evolved, so did the search for next-generation vaccines. Dr. Sehulong Robert Moraba contributed to this effort as a Sub-Investigator in the Phase 1 GO-012 trial. This study assessed the safety and tolerability of two vaccine candidates, GRT-R912 and GRT-R914, as prime and/or boost regimens.
The study enrolled a diverse cohort including SARS-CoV-2 naive individuals, convalescent subjects, and people living with HIV (SAHPRA ref: 20210435). Dr. Moraba’s work ensured the safe evaluation of these novel candidates in populations often underrepresented in early research, contributing to a more inclusive vaccine development landscape.
